These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 29516231)

  • 1. A call for improved transparency in financial aspects of clinical trials: a case study of the CREATE-X trial in the New England Journal of Medicine.
    Ozaki A; Takita M; Tanimoto T
    Invest New Drugs; 2018 Jun; 36(3):517-522. PubMed ID: 29516231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conflict of Interest and the CREATE-X Trial in the New England Journal of Medicine.
    Ozaki A
    Sci Eng Ethics; 2018 Dec; 24(6):1809-1811. PubMed ID: 28916944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accuracy of post-publication Financial Conflict of Interest corrections in medical research: A secondary analysis of pharmaceutical company payments to the authors of the CREATE-X trial report in the New England Journal of Medicine.
    Ozaki A; Saito H; Sawano T; Shimada Y; Tanimoto T
    Bioethics; 2021 Sep; 35(7):704-713. PubMed ID: 34137057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Five-step authorship framework to improve transparency in disclosing contributors to industry-sponsored clinical trial publications.
    Marušić A; Hren D; Mansi B; Lineberry N; Bhattacharya A; Garrity M; Clark J; Gesell T; Glasser S; Gonzalez J; Hustad C; Lannon MM; Mooney LA; Peña T
    BMC Med; 2014 Oct; 12():197. PubMed ID: 25604352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary outcome switching among drug trials with and without principal investigator financial ties to industry: a cross-sectional study.
    Jones CW; Misemer BS; Platts-Mills TF; Ahn R; Woodbridge A; Abraham A; Saba S; Korenstein D; Madden E; Keyhani S
    BMJ Open; 2018 Feb; 8(2):e019831. PubMed ID: 29439079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer vaccine THERATOPE- Biomira.
    Adis International Ltd
    Drugs R D; 2003; 4(4):236-40. PubMed ID: 12848588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
    Masuda N; Lee SJ; Ohtani S; Im YH; Lee ES; Yokota I; Kuroi K; Im SA; Park BW; Kim SB; Yanagita Y; Ohno S; Takao S; Aogi K; Iwata H; Jeong J; Kim A; Park KH; Sasano H; Ohashi Y; Toi M
    N Engl J Med; 2017 Jun; 376(22):2147-2159. PubMed ID: 28564564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry.
    Perlis RH; Perlis CS; Wu Y; Hwang C; Joseph M; Nierenberg AA
    Am J Psychiatry; 2005 Oct; 162(10):1957-60. PubMed ID: 16199844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transparency and credibility of industry-sponsored clinical trial publications: a survey of journal editors.
    Mooney LA; Fay L; DeCastro B; Zanki TA; Mansi B
    Curr Med Res Opin; 2019 Jul; 35(7):1221-1230. PubMed ID: 30648455
    [No Abstract]   [Full Text] [Related]  

  • 11. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Financial ties of principal investigators and randomized controlled trial outcomes: cross sectional study.
    Ahn R; Woodbridge A; Abraham A; Saba S; Korenstein D; Madden E; Boscardin WJ; Keyhani S
    BMJ; 2017 Jan; 356():i6770. PubMed ID: 28096109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial.
    Shiroiwa T; Fukuda T; Shimozuma K; Mouri M; Hagiwara Y; Kawahara T; Ohsumi S; Hozumi Y; Sagara Y; Ohashi Y; Mukai H
    BMC Cancer; 2017 Nov; 17(1):773. PubMed ID: 29149882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Financial ties between DSM-IV panel members and the pharmaceutical industry.
    Cosgrove L; Krimsky S; Vijayaraghavan M; Schneider L
    Psychother Psychosom; 2006; 75(3):154-60. PubMed ID: 16636630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial.
    Hamaguchi T; Shimada Y; Mizusawa J; Kinugasa Y; Kanemitsu Y; Ohue M; Fujii S; Takiguchi N; Yatsuoka T; Takii Y; Ojima H; Masuko H; Kubo Y; Mishima H; Yamaguchi T; Bando H; Sato T; Kato T; Nakamura K; Fukuda H; Moriya Y
    Lancet Gastroenterol Hepatol; 2018 Jan; 3(1):47-56. PubMed ID: 29079411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Payments by US pharmaceutical and medical device manufacturers to US medical journal editors: retrospective observational study.
    Liu JJ; Bell CM; Matelski JJ; Detsky AS; Cram P
    BMJ; 2017 Oct; 359():j4619. PubMed ID: 29074628
    [No Abstract]   [Full Text] [Related]  

  • 17. Conflict of Interest Disclosure in a Top-Tier Portuguese Medical Journal.
    Fonseca NM
    Acta Med Port; 2017 Sep; 30(9):652-655. PubMed ID: 29025532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and planned trials with capecitabine in adjuvant/neoadjuvant therapy of breast cancer.
    Livingston R
    Oncology (Williston Park); 2002 Oct; 16(10 Suppl 12):29-32. PubMed ID: 12435177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments.
    Roseman M; Milette K; Bero LA; Coyne JC; Lexchin J; Turner EH; Thombs BD
    JAMA; 2011 Mar; 305(10):1008-17. PubMed ID: 21386079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trust and transparency: patient perceptions of physicians' financial relationships with pharmaceutical companies.
    Perry JE; Cox D; Cox AD
    J Law Med Ethics; 2014; 42(4):475-91. PubMed ID: 25565614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.